{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-062296","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.824373+00:00","generated_at":"2026-06-01T21:31:48.733994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Replimune posts Q4 net loss $55.1M; RP1 melanoma BLA on track for 2H 2024","bullets":["Net loss of $55.1M for Q4 FY2024; full-year net loss $215.8M vs $174.3M prior year.","Cash, equivalents & investments $420.7M; cash runway projected into 2H 2026.","Primary analysis of IGNYTE trial (RP1 + nivolumab) in anti-PD1 failed melanoma expected Q2 2024.","BLA submission for RP1 in anti-PD1 failed melanoma planned for 2H 2024 after positive FDA CMC meeting.","First patient enrollment in Phase 3 IGNYTE-3 confirmatory trial expected 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-062296","json":"https://secwatch.observer/filing/0001104659-24-062296.json","markdown":"https://secwatch.observer/filing/0001104659-24-062296.md","text":"https://secwatch.observer/filing/0001104659-24-062296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/0001104659-24-062296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/tm2413978d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:31:48.733994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18ed1f160221ac0e65836bbbdba69fdbbdcd1890","claim":"Replimune Group, Inc. reported financial results for the fourth quarter and year ended March 31, 2024.","evidence_excerpt":"Replimune Group, Inc. (the \"Company\") issued a news release announcing its financial results for the fourth quarter and year ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737953/000110465924062296/0001104659-24-062296-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended March 31, 2024"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}